TAVI.today
Home
Latest Developments
Treatment & Guidelines
Clinical Evidence
Resources
Sign-up to Newsletter
Language: English
Language: English
Deutsch
Italian
Spanish

TAVI.today

edwards-logo-2-1-1.svg

Clinical evidence

Find out more about the evidence that supports the use of TAVI to treat patients with severe aortic stenosis (sAS).1-8 TAVI has been shown to benefit a wide range of sAS patients, including those with differing levels of surgical risk, patients with the typical comorbidities and risk factors associated with sAS.6-11

TAVI Trials

Discover more about the trials that have demonstrated comparable or better outcomes with TAVI compared with surgery (sAVR) in sAS patients with low, intermediate or high surgical risk. In addition, see the trial of TAVI versus standard treatment in patients with inoperable aortic stenosis.1-8
Valve-in-valve-TAVI-procedures

Low risk

PARTNER 3 Trial

Intermediate risk


PARTNER IIA Trial

High risk


PARTNER 1A Trial

Inoperable


PARTNER 1B Trial
Active-patient-post-TAVI-procedure

Quality of life

At 1 month post-intervention, health status was significantly better in patients who underwent TAVI compared to those who underwent sAVR.  TAVI was also associated with health status benefits at 12 months compared with sAVR in low surgical risk patients.12-14
Read more

Patient conditions and special risks

Many patients have multiple co-morbidities, which can make treatment decisions less clear. The following page provides valuable insights on how to manage these clinically challenging patients.

Coming soon
TAVI-patient

Patient conditions and special risks

Many patients have multiple co-morbidities, which can make treatment decisions less clear. The following page provides valuable insights on how to manage these clinically challenging patients.

Coming soon
TAVI-patient
Rectangle-39

Healthcare system impact

Examine the data that show TAVI has a number of benefits for healthcare systems. This includes low complication rates,9 shorter procedure time,10 faster recovery,12 and reduced length of hospital stays.3,5
Read more

TAVI valve durability

Valve durability is a key consideration for intervention choice. Assess the follow-up data from the PARTNER 3 studies, which establish the durability of the SAPIEN valves used in TAVI, in addition to 10-year real-world data.5,6
Read more

Stay informed with our newsletter

By providing your personal information, you agree to allow Edwards Lifesciences and its agents to use this information to communicate with you in the future, including information about services, events, and programs. Edwards Lifesciences and its agents will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Edwards Lifesciences and its agents, Edwards Lifesciences will use your information in accordance with the Edwards privacy policy.
Our monthly updates provide you the latest developments in TAVI and aortic stenosis.     Read more

References

  • 1Leon MB, Smith CR, Mack M, et al. N Engl J Med 2010; 363:1597-1607.
  • 2Smith CR, Leon MB, Mack MJ, et al. N Engl J Med 2011;364:2187-2198.
  • 3Leon MB, Smith CR, Mack MJ, et al. N Engl J Med 2016;374:1609-1620.
  • 4Kapadia SR, Leon MB, Makkar RR, et al. Lancet 2015;385:2485-2491.
  • 5Thourani VH, Kodali S, Makkar RR, et al. Lancet 2016;387:2218-2225.
  • 6Mack MJ, Leon MB, Smith CR, et al. Lancet 2015;385:2477-2484.
  • 7Webb JG, Doshi D, Mack MJ, et al. JACC Cardiovasc Interv 2015;8:1797-1806.
  • 8Mack MJ et al. N Engl J Med. 2019;380(18):1695-1705.
  • 9Tamburino C, Barbanti M, Capodanno D et al. Am J Cardiol 2012;109:1487–1493.
  • 10Hamm CW, Möllmann H, Holzhey D et al. Eur Heart J 2014;35:1588–1598.
  • 11Kleczyński, P, Bagieński M, Sorysz D, et al. Kardiol Pol 2014;72:612–616.
  • 12Baron SJ, Magnuson EA, Lu M, et al. J Am Coll Cardiol 2019;74(23):2833-2842.
  • 13Baron SJ, Arnold SV, Wang K, et al. JAMA Cardiol 2017;2:837-845.
  • 14Reynolds MR, Magnuson EA, Wang K, et al. J Am Coll Cardiol 2012;60:548-558.

Share this page on:

Facebook Twitter Linkedin Envelope
Latest Developments

Treatment & Guidelines

Clinical Evidence
Resources

Contact Edwards

Sitemap
Privacy Policy

Legal Terms

For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable). Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity. 

Edwards, Edwards Lifesciences, the stylized E logo, PARTNER, PARTNER II, PARTNER 3, SAPIEN, and SAPIEN 3 are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners. 

© 2023 Edwards Lifesciences Corporation. All rights reserved. PP–EU-0768  v1.0

Stäng filmen

Help us create better content with 3 short questions.

Content relating to Tavi.today is intended for healthcare professionals. Click OK to confirm you are a healthcare professional and proceed.
OK
Skip to content